Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research note issued to investors on Sunday morning. The firm issued a sell rating on the stock.

Navidea Biopharmaceuticals Stock Performance

NAVB opened at $0.00 on Friday. Navidea Biopharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.13.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.